Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is involved in the growth of human colon tumor


After analysing gene-expression profiles of colon cancers on a cDNA microarray containing cDNAs corresponding to 23 040 human genes, we focused on a gene annotated as C10orf3 (chromosome 10 open reading frame 3), whose expression was elevated in colorectal cancers (CRC) as well as in tumors arising in the stomach, lung, pancreas, and breast. The gene encodes a putative 464-amino-acid protein containing a domain known as AAA (ATPases associated with a variety of cellular activities). Western blot analysis using an antibody to the gene product confirmed that the protein was overexpressed in nine of the 15 clinical cancer tissues examined, compared to corresponding noncancerous epithelial cells. A subsequent proteomics analysis revealed that C10orf3 product associated with the product of tumor susceptibility gene 101 (TSG101), and that C10orf3 downregulated TSG101 in a post-transcriptional manner. Expression of short interfering RNA in cells derived from CRC caused significant decreases in C10orf3 expression and inhibited growth of the transfected cells, which was associated with increased apoptotic cells. These data suggest that elevated C10orf3 expression might play an essential role in the growth of cancer cells, and that suppression of C10orf3-mediated signal transduction may be a novel therapeutic strategy to a wide range of human tumors.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4

Accession codes




  • Bishop N, Woodman P . (2001). J. Biol Chem 276: 11735–11742.

  • Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al. (2000). Lancet 355: 1041–1047.

  • Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang HE et al. (2001). Cell 107: 55–65.

  • Gridelli C, Rossi A, Maione P . (2003). Oncogene 22: 6629–6638.

  • Hasegawa S, Furukawa Y, Li M, Satoh S, Kato T, Watanabe T et al. (2002). Cancer Res 62: 7012–7017.

  • Jessberger R . (2002). Nat Rev Mol Cell Biol 3: 767–778.

  • Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S et al. (2003). Oncogene 22: 2192–2205.

  • Lee MP, Feinberg AP . (1997). Cancer Res 57: 3131–3134.

  • Li L, Cohen SN . (1996). Cell 85: 319–329.

  • Li L, Liao J, Ruland J, Mak TW, Cohen SN . (2001). Proc Natl Acad Sci USA 98: 1619–1624.

  • Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC, Nakamura Y . (2002). Oncogene 21: 4120–4128.

  • Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J . (2001). Cancer Res 61: 4744–4749.

  • Nakamura T, Furukawa Y, Nakagawa H, Tsunoda T, Ohigashi H, Murata K et al. (2004). Oncogene 23: 2385–2400.

  • Neuwald AF, Aravind L, Spouge JL, Koonin EV . (1999). Genome Res 9: 27–43.

  • Nishidate T, Katagiri T, Lin ML, Mano Y, Miki Y, Kasumi F et al. (2004). Int J Oncol 25: 797–819.

  • Obama K, Ura K, Katagiri T, Tsunoda T, Nomura A, Satoh S et al. (2005). Hepatology 41: 1339–1348.

  • O'Dwyer ME, Druker BJ . (2000). Curr Opin Oncol 12: 594–597.

  • Okabe H, Satoh S, Furukawa Y, Kato T, Hasegawa S, Nakajima Y et al. (2003). Cancer Res 63: 3043–3048.

  • Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y et al. (2001). Cancer Res 61: 2129–2137.

  • Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al. (2000). N Engl J Med 343: 905–914.

  • Shimokawa T, Furukawa Y, Sakai M, Li M, Miwa N, Lin YM et al. (2003). Cancer Res 63: 6116–6120.

  • Sun Z, Pan J, Bubley G, Balk SP . (1997). Oncogene 15: 3121–3125.

  • Wagner KU, Krempler A, Qi Y, Park K, Henry MD, Triplett AA et al. (2003). Mol Cell Biol 23: 150–162.

  • Walt G . (2004). BMJ 328: 6.

  • Xie W, Li L, Cohen SN . (1998). Proc Natl Acad Sci USA 95: 1595–1600.

  • Zhong Q, Chen Y, Jones D, Lee WH . (1998). Cancer Res 58: 2699–2702.

  • Zhu G, Gilchrist R, Borley N, Chng HW, Morgan M, Marshall JF et al. (2004). Int J Cancer 109: 541–547.

Download references


We appreciate the technical assistance of Yoshika Sakamoto, Noriko Ikawa, and Tae Makino and the contributions of Dr Toyomasa Katagiri for the preparation of anti-C10orf3 antibody, and are grateful to Ryuji Hamamoto and Kazutaka Obama for helpful discussions. This work was supported in part by the Research for the Future Program Grant #00L01402 from the Japan Society for the Promotion of Science.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Y Furukawa.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sakai, M., Shimokawa, T., Kobayashi, T. et al. Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is involved in the growth of human colon tumor. Oncogene 25, 480–486 (2006).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • colon
  • cancer
  • C10orf3
  • TSG101

This article is cited by


Quick links